D'Onofrio, 2019 - Google Patents
Necroptosis and Its Interactions with Focal Adhesion Kinase (FAK) and Extracellular Receptor Kinase (ERK1/2) Following Optic Nerve InjuryD'Onofrio, 2019
- Document ID
- 7657959211131479047
- Author
- D'Onofrio P
- Publication year
External Links
Snippet
Necroptosis and Its Interactions with Focal Adhesion Kinase (FAK) and Extracellular Receptor
Kinase (ERK1/2) Following Optic Nerve Injury Necroptosis and Its Interactions with Focal
Adhesion Kinase (FAK) and Extracellular Receptor Kinase (ERK1/2) Following Optic Nerve …
- 230000021597 necroptosis 0 title description 334
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ono et al. | Calpain research for drug discovery: challenges and potential | |
| Wang et al. | Salubrinal offers neuroprotection through suppressing endoplasmic reticulum stress, autophagy and apoptosis in a mouse traumatic brain injury model | |
| Tanida et al. | LC3 conjugation system in mammalian autophagy | |
| Gasse et al. | Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis | |
| Damme et al. | Autophagy in neuronal cells: general principles and physiological and pathological functions | |
| Kannan et al. | Novel roles for α-crystallins in retinal function and disease | |
| Zhao et al. | Flavonoid VI-16 protects against DSS-induced colitis by inhibiting Txnip-dependent NLRP3 inflammasome activation in macrophages via reducing oxidative stress | |
| Lei et al. | Synergistic neuroprotective effect of rasagiline and idebenone against retinal ischemia-reperfusion injury via the Lin28-let-7-Dicer pathway | |
| US20100068308A1 (en) | Regulation of GSK-3alpha activity for the treatment or prevention of Alzheimer's disease | |
| Piacentini et al. | Transglutaminase 2 at the crossroads between cell death and survival | |
| Piacentini et al. | Type 2 transglutaminase in neurodegenerative diseases: the mitochondrial connection | |
| JP2021527669A (en) | Compositions and Methods for Relieving or Treating Fibrosis | |
| EP1545287B1 (en) | Vasoregulating compounds and methods of their use | |
| D'Onofrio | Necroptosis and Its Interactions with Focal Adhesion Kinase (FAK) and Extracellular Receptor Kinase (ERK1/2) Following Optic Nerve Injury | |
| Wang et al. | Chronic rapamycin treatment improved metabolic phenotype but inhibited adipose tissue browning in high-fat diet-fed C57BL/6J mice | |
| JP2023509187A (en) | Compounds and methods for treating Alzheimer's disease | |
| Rosa | Exploring the effect of NLRP3 Inflammasome inhibition in the ex vivo model of epileptogenesis | |
| WO2007047950A2 (en) | Use of sumoylation inhibitors for the treatment of neurodegenerative disease | |
| Li et al. | The role of TRPC6-mediated autophagy in myocardial ischaemia/reperfusion injury | |
| Talley | Developing Caspase-1 Biosensors to Monitor Inflammation in Vitro and in Vivo | |
| Yan et al. | The UFMylation pathway is impaired in Alzheimer's disease | |
| Li et al. | VX‐765 alleviates motor and cognitive impairments via inhibiting PANoptosis activation in the neonatal rats after hypoxic–ischemic brain damage | |
| Li et al. | Proteomic Analysis of the Supernatant from Bone Marrow Mesenchymal Stem Cells under High Glucose Conditions | |
| Lew | Contribution of Microglia and Müller Cells to Retinal Degeneration Due to MerTk Deficiency | |
| Simon | Role of Müller cells in the onset and progression of neuronal degeneration after acute retinal ischemia |